Send us a textEditor-in-Chief Sue Yom co-hosts with Dr. Claire Vanpouille-Box, Assistant Professor at Weill Cornell Medicine, Associate Editor in Biology at our journal, and expert on radiation and immunotherapy, interviewing Associate Professor Dr. Tsubasa Watanabe and Postdoctoral Scholar Dr. Genki Sato from the Institute for Integrated Radiation and Nuclear Science at Kyoto University, who were supervising and first authors on our recent new publication, “Conventional fractionated elective nodal irradiation preserves early antitumor immunity and efficacy compared to hypofractionated protocols”, joined by Dr. Jonathan Schoenfeld, Professor in the Department of Radiotherapy at Brigham and Women’s Hospital and supervising author of the accompanying editorial, “The Ongoing Challenge of Radiation-Immunotherapy Optimization: From Preclinical Insights to Clinical Practice.”
Send us a textEditor-in-Chief Sue Yom co-hosts with Dr. Sarah Milgrom, Associate Professor in the Department of Radiation Oncology at the University of Colorado and Section Editor for Lymphoma, interviewing Dr. Brad Hoppe, Professor in the Department of Radiation Oncology and Medical Director of Particle Therapy from Mayo Clinic Jacksonville, who was last author on “The Role of Radiation Therapy in the Management of Grey Zone Lymphoma,” first author on “Comparison of Contemporary Radiotherapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331,” and submitting author of a striking art cover called “Set in Bloom” created by his young adult patient Katherine Beatty, a survivor of Gray Zone lymphoma, as well as Dr. Belinda Campbell, Associate Professor and Deputy Director of Radiation Oncology at Peter MacCallum Cancer Centre and first author of “Radiation therapy utilization for primary cutaneous T-cell lymphoma is lowest amongst patients living in the most geographically accessible areas; an Australian study.”
Send us a textFor ASTRO 2025, our Editor-in-Chief Dr. Sue Yom hosts Dr. Minesh Mehta, Chief, Deputy Director and John and Mary Lou Dasburg Endowed Chair in Radiation Oncology at Baptist Health Miami Cancer Institute and first author of the article “Tumor Treating Fields (TTFields) therapy after stereotactic radiosurgery for brain metastases from non-small cell lung cancer: final results of the phase 3 METIS study”; Dr. Cliff Robinson, Professor and Chief of SBRT at Washington University in St. Louis, Thoracic Section Editor, and supervising author of Stereotactic Arrhythmia Radiotherapy (STAR) vs Repeat Catheter Ablation for High-Risk Refractory Ventricular Tachycardia: 3-Year Safety and Efficacy Outcomes; and Dr. Alexa Dang, Clinical Instructor in Radiation Oncology at BC Cancer in Vancouver and first author of Dosimetric Outcomes for Stereotactic Radiotherapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial.
Send us a textEditor-in-Chief Dr. Sue Yom hosts Dr. Ben Corn, Professor of Oncology and Director of the Institute for the Study of Hope, Dignity & Wellbeing at Hebrew University School of Medicine in Jerusalem, and first author of our article published this month, ““Hope” Drives Quality of Life in Patients With Brain Metastases, But, the “Hope Center” Remains Elusive: An Analysis of NRG-CC003”; Dr. Vinai Gondi, Clinical Associate Professor and Service Line Director of Radiation Oncology in the Northwestern Medicine West Region, co-author on this paper and Principal Investigator of the parent clinical trial that enabled this study, NRG-CC003; and Dr. Tracy Balboni, Professor and Program Director of the Harvard Radiation Oncology Program, Director of Skeletal Radiation Oncology at Dana-Farber Cancer Center, Co-Director of the Initiative on Health, Spirituality, and Religion at Harvard, and the author of an accompanying editorial to this article, “Hope in Wisdom Past and for Future Clinical Trials.”
Send us a textASTRO has recently updated guidelines for post mastectomy radiotherapy (PMRT) to align practice with outcomes from multiple newly published studies for locally advanced breast cancer published over the past decade. This podcast, led by Melissa Pulfer Mitchell, MD, features lead authors of the new ASTRO PMRT guidelines Kathleen C. Horst, MD, and Rachel B. Jimenez, MD, and highlights the main questions answered by the new guidelines, as well as limitations of this expert consensus and lingering questions to be addressed.
Send us a textDr. Sue Yom, Editor in Chief, co-hosts with Deputy Editor Dr. Alison Tree, in discussion/debate with Dr. John Floberg, Associate Professor and Director of Theranostics in the Department of Human Oncology at the University of Wisconsin and last author of “Severe Late Toxicities (Grade 3-5) with 13 Years of Follow-up after Hypofractionated Postprostatectomy Radiotherapy”; Dr. Paul Sargos, Head of the Department of Radiotherapy at the Institut Bergonié in Bordeaux, France and last author of an accompanying editorial, ”Hypofractionated radiotherapy for prostate cancer in the postoperative setting: is it capable of going the distance?”; and Dr. Ron Chen, Professor and Chair of Radiation Oncology at the University of Kansas, an Associate Editor at the journal, and a co-chair of NRG-GU003, who was corresponding author on a counterpoint editorial, “Long Term Outcomes in Hypofractionated Post-Prostatectomy Radiation: Cautionary Tale or Expected Findings?”
Send us a textEditor-in-Chief Sue Yom hosts a discussion of lung cancer reirradiation with Dr. Charles Simone, Chief Medical Officer of the New York Proton Center and Full Member at Memorial Sloan Kettering and Dr. Kristen Higgins, Chief Clinical Officer for City of Hope Cancer Center Atlanta, first and co authors on a paper entitled “American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary.”
Send us a textEditor in Chief Dr. Sue Yom hosts a discussion of reirradiation planning based on the Michigan model of the special medical physics consultation, as explained by guests Dr. Kelly Paradis, Associate Professor of Medical Physics in the Department of Radiation Oncology at the University of Michigan, and Dr. Martha Matuszak, the Laurie Snow Professor of Radiation Oncology and Associate Chair for Physics in the same group, who were first and co-last author on the article, “Reirradiation Special Medical Physics Consultations: Lessons Learned From Nearly 3000 Courses of Treatment.”
Send us a textDr. Sue Yom, our Editor in Chief, hosts a discussion of workforce issues related to adaptive radiation therapy, with guests Dr. Lauren Henke, Associate Professor of Radiation Oncology at University Hospitals, Case Western Reserve University and Director of her department’s Residency and GI Programs, and last author of “Quality and Safety Considerations for Adaptive Radiation Therapy: An ASTRO White Paper” and Dr. Chirag Shah, Chair of the Allegheny Health Network Cancer Institute’s Division of Radiation Oncology and first author of an editorial from the ASTRO Workforce Committee entitled “Adaptive Radiation Therapy: Workforce Implications.”
Send us a textASTRO has recently released its first consensus guidelines on the treatment of anal cancer. This podcast, led by Michael Buckstein, MD PhD, features Dr. Mary Feng, lead author of the guidelines, and Dr. Chris Hallemeier as they discuss the nuances of the new guidelines, especially as it pertains to the more challenging aspects involving radiation for anal cancer. The podcast also explores some of the newer aspects of treatment for this rare disease and where we might be headed in the future.
Send us a textEditor in Chief Sue Yom hosts a discussion with Dr. Michelle Kim (CNS, University of Michigan), Dr. Michael Chuong (GI, Miami Cancer Institute), and Dr. Alison Tree (GU/editorials, The Royal Marsden NHS Foundation Trust), highlighting their top picks from their sections of the special issue.
Send us a textEditor in Chief Sue Yom hosts four of our artists – Jen Bellon, our journal’s Art Editor, who was previously at Dana Farber Cancer Institute/Brigham & Women’s Hospital, and now works as an independent art consultant; Annie Lavigne, Assistant Professor of Radiation Oncology at Johns Hopkins University; Josh No, Attending Physician at Kaiser Permanente; and Tony Orlina, Lead Dosimetrist at Dana Farber Cancer Center. They discuss the role of art in their lives, stories of their Red Journal cover artworks, and what they see as the role of art in medicine.
Send us a textEditor in Chief Dr. Sue Yom hosts a discussion with Dr. Ying Xiao, Professor of Radiation Oncology at the University of Pennsylvania and a leader of the Center for Innovation in Radiation Oncology at NRG Oncology, and Dr. Jeffrey Buchsbaum, Medical Officer in the Radiation Research Program of the National Cancer Institute at the National Institutes of Health. They are the first and last authors of an article this month, Embracing the Future of Clinical Trials in Radiation Therapy: An NRG Oncology CIRO Technology Retreat White Paper on Pioneering Technologies and AI-Driven Solutions.
Send us a textEditor in Chief Dr. Sue Yom hosts a discussion on the role of radiation for gallbladder cancer, as it is managed in India versus the U.S. Guests are Section Editor Dr. Michael Chuong, Vice Chair and Medical Director of Radiation Oncology at Miami Cancer Institute, and Dr. Sushma Agrawal, Professor from the Department of Radiotherapy at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lacknow, India, RACE-GB Principal Investigator, and first author of the primary trial report, A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB Study.
Send us a textIn this episode of the PRO podcast, join host Michael Buckstein, MD, PhD, as he sits down with Jennifer Wo, MD and Ann Raldow, MD, MPH to discuss the latest updates to the ASTRO Rectal Cancer Guidelines. In this episode, they break down key recommendations, the evolving role of radiation in rectal cancer management, and how these guidelines impact clinical decision-making. Tune in for expert insights on the latest evidence, practical applications, and what these updates mean for patient care.
Send us a textDr. Sue Yom, Editor in Chief, co-hosts with Dr. Lachlan McDowell, Consultant Radiation Oncologist at the Princess Alexandra Hospital in Queensland, Australia and our journal's Head and Neck Cancer Section Editor. Guests are Dr. Sean McBride, Radiation Oncologist at Memorial Sloan Kettering Cancer Center and Chief of External Beam Radiotherapy at the Manhattan site, who authored an editorial, Oligometastatic HNSCC: Is SABR the Solution?, and Dr. Juliette Thariat, Professor in Radiation Oncology at Cancer Center Baclesse in Normandy, France, Secrétaire Nationale at the GORTEC, and first author of our featured article, Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.
Send us a textIn this PRO podcast, Bisham Chera MD, FASTRO, Danielle Margalit, MD, MPH, and David Sher, MD, discuss the recently published ASTRO clinical practice guideline of Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma. This manuscript was published in print in the September/October 2024 issue and was the 3rd most downloaded PRO article in 2024. Listen for their lively and meaningful discussion of the key recommendations and controversies.
Send us a textDr. Sue Yom, Editor in Chief, hosts Dr. Kristin Hsieh, radiation oncology resident at Icahn School of Medicine at Mount Sinai and member of the SWRO mentorship committee; Dr. Crystal Seldon Taswell, Assistant Professor in the Department of Radiation Oncology at the University of Miami and past Chair of SWRO; Dr. Jennifer Croke, radiation oncologist at Princess Margaret Cancer Center and Associate Professor and Director of Fellowship at the University of Toronto; and Dr. Reshma Jagsi, the Lawrence W. Davis Professor and Chair of the Department of Radiation Oncology at at Emory University. All were co-authors on this month's featured publication, A 5-Year, Multi-Institutional Mentorship Program in Radiation Oncology: The Society for Women in Radiation Oncology Experience.
Send us a textOur Editor-in-Chief Dr. Sue Yom co-hosts with Dr. Henning Willers, our journal's Biology Section Editor and Associate Professor of Radiation Oncology at Massachusetts General Hospital. Guests are Dr. Simon Powell, Chair of Memorial Sloan Kettering Cancer Center Department of Radiation Oncology, who joins us as the co-last author of a new publication, Increased synthetic cytotoxicity of combinatorial chemoradiotherapy in homologous recombination deficient tumors, and Dr. Kerstin Borkmann, Professor of Radiobiology at the University Clinic Hamburg Eppendorf and Biology Associate Editor for our journal. She is the co-author of the accompanying editorial, BRCAness identifies synthetic cytotoxicity between cisplatin and RT.
Send us a textEditor-in-Chief, Robert Amdur, MD explains a relatively new form of narrative writing called the Micro-Story, which is a subset of the writing genre called Flash Fiction. The presentation is based on two papers published in the January/February 2025 issue of PRO (2025, Issue 1, January/February). One paper is the first Micro-Story ever published in PRO with title: "The Black Car (Children Playing)." The second paper is an accompanying Editorial titled "Flash and FLASH: In Short, an Imaginary Bridge."
Send us a textDr. Sue Yom, Editor in Chief, hosts guests Dr. Cristian Udovicich, a Fellow in Radiation Oncology at the University of Toronto's Sunnybrook Odette Cancer Centre, and Dr. Angela Jia, Assistant Professor and Assistant Residency Program Director at University Hospitals Cleveland Medical Center, who were the first and second authors of "Evolving Paradigms in Prostate Cancer: The Integral Role of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging and Therapeutic Decision-Making." In addition, we review long-term SBRT results with Dr. Andrew Loblaw, Full Professor in the Department of Radiation Oncology and Institute of Health Policy, Management and Evaluation at Sunnybrook Health Science Center at the University of Toronto and supervising author of "Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials," and Dr. Constantinos Zamboglou, Deputy Medical Director at the German Oncology Center in Limassol, Cyprus and first author of an accompanying editorial, "Stereotactic Body Radiotherapy for Prostate Cancer is Getting Mature: 10-Year Outcomes From Three Prospective Trials."
Send us a textThis podcast discussed the topic of "Improving consistency and reducing human bias for physicians’ target contouring using AI auto-segmentation." Experts joining the discussion include Steve Jiang, PhD, Professor and Vice Chair in Department of Radiation Oncology at University of Texas Southwestern and Director of Medical Artificial Intelligence and Automation Lab, Nathan Yu, MD, Assistant Professor in Department of Radiation Oncology, Mayo Clinic Arizona, and Yi Rong, PhD, Professor and Lead photon physicist in Department of Radiation Oncology at Mayo Clinic Arizona. This podcast focused on the utility of AI in automatic segmentation of medical imaging and the challenges related to physician variability in clinical practice. We discussed various strategies for addressing these challenges, including developing physician-style aware AI models and balancing standardization with personalization in AI tool development and deployment. The emphasis is on the feasibility and clinical utility of using AI to improve the accuracy and efficiency of medical image segmentation while respecting the art and personalization inherent in clinical medicine.
Send us a textEditor in Chief Dr. Sue Yom and Associate Editor Dr. Neil Taunk, Assistant Professor of Radiation Oncology and Chief of the Gynecologic Radiation Service at the University of Pennsylvania, co-host a podcast on "Biomarker expression and impact on clinical outcomes in an international study of chemoradiation and MRI-based image-guided brachytherapy for locally advanced cervical cancer: BIOEMBRACE," with guests Dr. Supriya Chopra, Professor at Tata Memorial Centre in Mumbai, India, and Dr. Remi Nout, Professor and Head of the Department of Radiotherapy of the Erasmus Medical Center, University Medical Center, in Rotterdam, Netherlands, who were the first and last authors and both principal investigators of the BIOEMBRACE study.
Send us a textEditor-in-Chief, Robert Amdur, MD and Resident Physician, Daniela Martir, MD discuss Partially Ablative Body Radiotherapy for Locally Advanced Unresectable Tumor. The discussion is based on a paper in PRO titled “Partially Ablative Body Radiotherapy (PABR): A Widely Applicable Planning Technique for Palliation of Locally Advanced Unresectable Tumors” (PMID 39393770).
Send us a textEditor-in-Chief Dr. Sue Yom hosts Dr. Mai Anh Huynh, Assistant Professor of Radiation Oncology at the Brigham and Women's Hospital / Dana-Farber Cancer Center who wrote an editorial this month, "The Hidden Benefits of Palliative Radiotherapy: When Radiation of Metastatic Disease is Not "Just" Palliative," Dr. David Palma, a Radiation Oncologist at the London Health Sciences Centre who co-authored, "Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase I Study of Stereotactic Ablative Radiotherapy for Poly-metastatic Disease", and Dr. Ethan Ludmir, Assistant Professor in the Departments of Gastrointestinal Radiation Oncology and Biostatistics at the University of Texas MD Anderson Cancer Center and supervising author of "Off-Protocol Radiotherapy in Phase III Metastatic Solid Tumor Trials." The group also discusses an article from this month's issue, "Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?"
Send us a textIn this podcast, we discuss the The Society of Thoracic Surgeons/American Society for Radiation Oncology Updated Clinical Practice Guidelines on Multimodality Therapy for Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction. Joining in the discussion are Dr. Stephanie Worrell, Associate Professor and Thoracic Section Chief in the Division of Cardiothoracic Surgery at the University of Arizona College of Medicine, and Dr. Karyn Goodman, Professor and Vice Chair for Research and Quality at the Icahn School of Medicine at Mount Sinai, and Associate Director for Clinical Research at The Tisch Cancer Institute, who served as chair and co-chair of the guideline panel, respectively. Together, we cover important updates and recommendations that incorporate surgical aspects into the multi-disciplinary management of this disease along with practical considerations for everyday practice. Additionally, we discuss in depth the recently presented ESOPEC trial presented at the 2024 ASCO annual meeting and how it has impacted the standard of care for esophageal cancers.
Send us a textDeputy Editor Salma Jabbour hosts Dr. Christopher Anker, Professor of Radiation Oncology and Program Co-Leader in the Cancer Host and Environment program at the University of Vermont Cancer Center, and Dr. Leila Tchelebi, Associate Professor of Radiation Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, respectively the first and second authors of a guideline published in this issue, Executive Summary of the American Radium Society Appropriate Use Criteria for Non-Operative Management for Rectal Adenocarcinoma: Systematic Review and Guidelines
Send us a textEditor in Chief Dr. Sue Yom co-hosts with Dr. Nicholas Zaorsky, an Associate Editor at the Journal and Associate Professor in the Department of Radiation Oncology at Case Western University Hospitals. We discuss three articles that are publishing rapid online for this meeting including Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial, with the Principal Investigator Dr. Vedang Murthy, Professor in the Department of Radiation Oncology at Tata Memorial Centre in Mumbai, and its accompanying editorial, Adjuvant Radiation Therapy for Locally Advanced Bladder Cancer: A Safe and Promising Emerging Treatment Option, with first author Dr. Brian Baumann, Radiation Oncologist at Springfield Clinic in Illinois. Relevant to this discussion is a paper appearing in this month's issue, The Value and Safety of Adjuvant Radiation Therapy After Radical Cystectomy in Locally Advanced Urothelial Bladder Cancer: A Controlled Randomized Study and its accompanying editorial, Is It Time to Reconsider the Place of Adjuvant Radiation Therapy After Radical Cystectomy? Finally, our third rapid online paper is Setting the Stage: Feasibility and Baseline Characteristics in the Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL) Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer, with Principal Investigator Dr. Jason Efstathiou, Professor of Radiation Oncology at Harvard Medical School, Massachusetts General Hospital.
Send us a textDr. Sue Yom, Editor in Chief, hosts Ms. Nina Levin, a Medical Physicist and PhD Candidate and Dr. Bjørn Grønberg, Professor and Consultant in medical oncology and radiotherapy, from the Department of Clinical and Molecular Medicine at the Norwegian University of Science and Technology, and Dr. Megan Daly, Professor from the University of California Davis and an Associate Editor at our journal. We discuss Ms. Levin’s and Dr. Grønberg’s article, Evaluation of radiotherapy treatment plans in a randomized phase II trial comparing two schedules of twice-daily thoracic radiotherapy in limited stage small-cell lung cancer, and its accompanying editorial, Toward the Optimal Delivery of Twice-Daily Thoracic Chemoradiation in Limited-Stage Small Cell Lung Cancer, as well as an article from the August 2024 issue, Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial.
